Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Sandostatin
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Sandostatin LAR 30mg inj vials
0803043N0BBAFAF
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 277 |
|
Sandostatin LAR 20mg inj vials
0803043N0BBAGAG
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 197 |
|
Sandostatin LAR 10mg inj vials
0803043N0BBAEAE
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 59 |
|
Sandostatin 100micrograms/1ml inj ampoules
0803043N0BBABAB
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 19 |
|
Sandostatin 50micrograms/1ml solution for injection ampoules
0803043N0BBAAAA
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 9 |
|
Sandostatin 500micrograms/1ml inj ampoules
0803043N0BBACAC
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | 7 |
|
Sandostatin 1mg/5ml solution for injection vials
0803043N0BBADAD
|
Sandostatin | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.